Veracyte | VCYT - Operating Profit


Veracyte reported $23.96M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Agenus USD 15.05M 656K Mar/2026
Agilent USD 399M 46M Mar/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -141.26M 182.07M Mar/2026
Bruker USD 69.6M 59.4M Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Illumina USD 260M 21M Jun/2026
Intrexon USD -60.84M 26.62M Jun/2024
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Laboratory Of America USD 456.7M 46.6M Jun/2026
Ligand Pharmaceuticals USD 56.62M 3.7M Jun/2026
Myriad Genetics USD -3M 20.3M Dec/2025
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Roche Holding CHF 11.46B 1.91B Jun/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Siemens EUR 3.19B 508M Jun/2026
Sonic Healthcare AUD 435.76M 193.66M Dec/2024
Thermo Fisher Scientific USD 2.18B 273M Jun/2026
Veracyte USD 23.96M 4.88M Jun/2026
Waters USD -86M 234M Jun/2026